The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis of cancer cell therapies based on information collected from numerous trusted and publicly available sources. We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication.
Cancer Cell Therapy Landscape
Interactive dashboard: The top graph serves as the filter to curate the following two graphs. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article published in June 2021.
Cancer Cell Therapy Analysis Publications
The most recent cancer cell therapy landscape publication is "The clinical pipeline for cancer cell therapies" in Nature Reviews Drug Discovery (June 2021).
Read more IO landscape publications
Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets.
Download a PDF of the latest CRI landscape figures
Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.
Subscribe to our email newsletter to receive the latest updates on our landscape analyses.
Do you want more information on the Clinical Accelerator? Contact us.